Aerie Pharmaceuticals, Inc.
(NASDAQ : AERI)

( )
AERI PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. 3.27%29.0714.1%$171.05m
ICLRICON plc 0.93%229.204.2%$156.70m
JAZZJazz Pharmaceuticals Plc 0.57%179.172.2%$142.15m
HZNPHorizon Therapeutics Plc 5.02%92.145.5%$124.53m
CTLTCatalent, Inc. 2.18%102.672.1%$105.63m
BHCBausch Health Cos., Inc. 3.27%29.070.0%$91.68m
SAVACassava Sciences, Inc. 8.31%40.920.0%$55.78m
UTHRUnited Therapeutics Corp. 2.12%197.8714.0%$55.65m
PRGOPerrigo Co. Plc 1.80%45.826.9%$49.71m
BLRXBioLineRx Ltd. 0.00%2.850.8%$38.97m
ARGXargenx SE 4.22%272.300.0%$38.23m
SAGESAGE Therapeutics, Inc. 2.03%70.867.6%$33.60m
PCRXPacira Biosciences, Inc. 1.22%62.219.9%$30.64m
AXSMAxsome Therapeutics, Inc. -2.68%58.421.9%$26.79m
RVMDRevolution Medicines, Inc. 4.07%31.990.0%$23.38m

Company Profile

Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.